[EN] SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS [FR] DÉRIVÉS SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE UTILISÉS EN TANT QU'INHIBITEURS DE BROMODOMAINES
The Synthesis and Resolution of 2,2‘-, 4,4‘-, and 6,6‘-Substituted Chiral Biphenyl Derivatives for Application in the Preparation of Chiral Materials
作者:Pedro J. Montoya-Pelaez、Yoon-Seo Uh、Christopher Lata、Matthew P. Thompson、Robert P. Lemieux、Cathleen M. Crudden
DOI:10.1021/jo060553d
日期:2006.8.1
Various routes were examined for the synthesis of chiral biphenyl species that are substituted at the 2,2‘, 4,4‘ and 6,6‘ positions. Because the biaryl bond is tetrasubstituted, many coupling reactions were not suitable. The most reliable coupling reaction proved to be the Ullmann, which gave the desired product in 82% yield. The products were required as the starting point for the preparation of chiral
[EN] SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONES EN TANT QU'INHIBITEURS DE BROMODOMAINE
申请人:ORION CORP
公开号:WO2015092118A1
公开(公告)日:2015-06-25
The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy, R1, R2, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.
Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same
申请人:Tzeng Cherng-Chyi
公开号:US20090111987A1
公开(公告)日:2009-04-30
Disclosed herein are novel imino-indeno[1,2-c]quinoline derivatives of formula (I):
or a pharmaceutically acceptable salt or solvate thereof,
wherein each of the substituents is given the definition as set forth in the Specification and Claims.
Also disclosed are the preparation processes of these derivatives, their synthetic precursors and their uses in the manufacture of pharmaceutical compositions for use in the treatment of cancers.